柯里拉京对人肝癌细胞增殖、迁移、侵袭和凋亡的影响  

Effects of corilagin on proliferation, migration, invasion and apoptosis of human hepatoma cells

作　　者：高金亭 江蜜 许杰 熊俊[2] Gao Jinting;Jiang Mi;Xu Jie;Xiong Jun(Department of Hepatobiliary Surgery,Shenzhen Nanshan District People’s Hospital,Shenzhen 518052,China;Department of Hepatobiliary Surgery,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,China;Yichang Hospital of Traditional Chinese Medicine,Clinical College of Traditional Chinese Medicine,China Three Gorges University,Hubei Functional Digestive System Diseases Clinical Research Center of Traditional Chinese Medicine,Yichang 443005,China)

机构地区：[1]深圳市南山区人民医院肝胆外科,518052 [2]华中科技大学同济医学院附属协和医院肝胆外科,武汉430022 [3]三峡大学中医临床学院宜昌市中医医院湖北省功能性消化系统疾病中医临床医学研究中心,443005

出　　处：《中华实验外科杂志》2022年第7期1281-1283,共3页Chinese Journal of Experimental Surgery

基　　金：深圳市卫生计生系统科研项目(SZXJ2018025);湖北省教育厅指导性项目(B2020021)。

摘　　要：目的观察柯里拉京对人肝癌细胞增殖、迁移、侵袭和凋亡的影响。方法人肝癌细胞(HepG2细胞系)、人正常肝细胞(LO2细胞株)均购自中国典型培养物保藏中心。用不同浓度的柯里拉京(0、6.25、12.5、25、50、100、200、400μg/ml)处理LO2细胞和HepG2细胞,用细胞计数试剂盒(CCK-8)法检测细胞活力,筛选出HepG2细胞的合适浓度范围。将HepG2细胞分为对照组(未行任何处理)、柯里拉京组(25、50、100μg/ml柯里拉京处理)、索拉非尼组(5μg/ml索拉非尼处理)、Tivantinib组(0.5μmol/L tivantinib处理),分别采用CCK-8法、划痕实验、Transwell实验和流式细胞术分别检测HepG2细胞的增殖、迁移、侵袭和凋亡。组间两两比较采用t检验。结果CCK-8结果显示,LO2和HepG2细胞活力均以浓度依赖的方式受到柯里拉京的抑制,当柯里拉京浓度为25、50、100μg/ml时,二者抑制程度具有显著差异(t=9.193、29.030、68.081,P<0.01);柯里拉京100μg/ml组HepG2细胞的增殖抑制率高于索拉非尼组和Tivantinib组[(56.38±1.42)%比(26.03±0.94)%、(36.25±1.11)%],差异有统计学意义(t=30.864、19.305,P<0.01)。划痕实验结果显示,柯里拉京100μg/ml组创面愈合率低于索拉非尼组和Tivantinib组[(12.33±0.98)%比(21.53±2.75)%、(28.41±2.81)%],差异有统计学意义(t=5.834、8.807,P<0.01)。Transwell实验结果显示,柯里拉京100μg/ml组侵袭细胞计数低于索拉非尼组和Tivantinib组[(123.70±18.96)个比(358.35±41.24)个、(342.18±33.75)个],差异有统计学意义(t=9.077、10.076,P<0.01)。流式细胞术结果显示,柯里拉京100μg/ml对HepG2细胞的诱导凋亡百分比高于索拉非尼组、Tivantinib组和对照组[(17.95±2.36)%比(5.77±1.08)%、(6.09±1.24)%、(2.35±0.28)%],差异有统计学意义(t=8.136、7.711、11.378,P<0.01)。结论柯里拉京可以抑制HepG2人肝癌细胞的增殖、迁移和侵袭,同时促进它的凋亡。Objective To study the effects of corilagin on proliferation,migration,invasion and apoptosis of human hepatoma cells.Methods Human hepatoma cells(HepG2 cell line)and human normal liver cells(LO2 cell line)were purchased from China Center for Type Culture Collection.LO2 cells and HepG2 cells were treated with different concentrations of corilagin(0,6.25,12.5,25,50,100,200 and 400μg/ml),and the cell viability was detected by cell counting kit-8(CCK-8)method to screen out the appropriate concentration range of HepG2 cells.HepG2 cells were divided into control group(without any treatment),corilagin group(treatment with 25,50 and 100μg/ml corilagin),sorafenib group(treatment with 5μg/ml sorafenib),tivantinib group(treatment with 0.5μmol/L tivantinib).Proliferation,migration,invasion and apoptosis of HepG2 cells were detected by CCK-8 assay,scratch assay,Transwell assay and flow cytometry,respectively.The measurement data were expressed as mean±standard deviation(SD),and t-test was used for pairwise comparison between groups.Results CCK-8 assay showed that both LO2 and HepG2 cells were inhibited by corilagin in a concentration-dependent manner,and there was a significant difference in inhibition degree between the two groups when corilagin concentration was 25,50 and 100μg/ml(t=9.193,29.030,68.081,P<0.01).The proliferation inhibition rate of HepG2 cells in 100μg/ml corilagin group was higher than that in sorafenib group and tivantinib group[(56.38±1.42)%vs.(26.03±0.94)%,(36.25±1.11)%],and the difference was statistically significant(t=30.864,19.305,P<0.01).Scratch test results showed that the wound healing rate in 100μg/ml corilagin group was lower than that in sorafenib group and tivantinib group[(12.33±0.98)%vs.(21.53±2.75)%,(28.41±2.81)%],and the difference was statistically significant(t=5.834,8.807,P<0.01).Transwell results showed that the number of invasive cells in 100μg/ml corilagin group was less than that in sorafenib group and tivantinib group[(123.70±18.96)vs.(358.35±41.24)and(342.18±33.7

关 键 词：柯里拉京 肝癌细胞 增殖 迁移 侵袭 凋亡 

分 类 号：R735.7[医药卫生—肿瘤]